Agios Pharmaceuticals AGIO Other accrued liabilities
Other accrued liabilities at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherAccruedLiabilitiesCurrent.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's other accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's other accrued liabilities?
- Agios Pharmaceuticals (AGIO) reported other accrued liabilities of $3.32M in Q1 2026.
- How has Agios Pharmaceuticals's other accrued liabilities changed year-over-year?
- Agios Pharmaceuticals's other accrued liabilities increased by 49.8% year-over-year, from $2.22M to $3.32M.
- What is the long-term trend for Agios Pharmaceuticals's other accrued liabilities?
- Over 5 years (2020 to 2025), Agios Pharmaceuticals's other accrued liabilities has grown at a 3.4% compound annual growth rate (CAGR), from $2.12M to $2.5M.